Opthea Limited Sponsored ADR ( (OPT) ) has shared an update.
Opthea Limited announced that its COAST Phase 3 trial, which evaluated the combination of sozinibercept and aflibercept for treating wet AMD, failed to meet its primary endpoint of improving best corrected visual acuity (BCVA) from baseline to week 52. The negative trial results have prompted Opthea to review its Development Funding Agreement, which could impact the company’s solvency if certain repayment triggers are activated. Discussions with investors are ongoing to explore potential pathways for the company’s clinical trial program and financial stability.
More about Opthea Limited Sponsored ADR
Opthea Limited is a clinical-stage biopharmaceutical company focused on developing novel therapies for treating retinal diseases, particularly wet age-related macular degeneration (wet AMD).
YTD Price Performance: -13.11%
Average Trading Volume: 37,070
Technical Sentiment Signal: Buy
Current Market Cap: $464.2M
Find detailed analytics on OPT stock on TipRanks’ Stock Analysis page.